miércoles, 25 de mayo de 2016

Announcement: FDA Webinar -Artificial Pancreas: A Dialogue between the FDA and the Diabetes Community Thursday, June 2, 2016; 2:00 -3:00 PM, Eastern Time

Diabetes Monitor

Artificial Pancreas: A Dialogue between the FDA and the Diabetes Community
On Thursday, June 2, 2016, the FDA will host a webinar to share general information about how the FDA regulates diabetes devices and ongoing efforts to accelerate the availability of artificial pancreas devices. The webinar will focus on current and emerging artificial pancreas technologies, and the FDA’s role in reviewing these technologies for safety and effectiveness.  Representatives from the FDA and the Diabetes Patient Advocacy Coalition will be available to answer questions from webinar participants. 
Webinar Details: Registration is not necessary.
Date: Thursday, June 2, 2016
Time: 2:00 -3:00 PM, Eastern Time
To hear the presentation and ask questions: Dial: 888-603-9738; passcode: 8218260 | International: 212-547-0409; passcode: 8218260
To view the webinar presentation you must download the free WebEx software plug-in:
·         Before the webinar, visit the WebEx Downloads webpage
·         Under the WebEx Event Manager heading select the download for your operating system.

On the day of the webinar, use the following link to view the presentation:https://www.mymeetings.com/nc/join.php?i=PWXW8131511&p=8218260&t=c
Target Audience: Diabetes patient groups, researchers, advocacy groups, industry
Following the webinar, a transcript and the video recording will be available athttp://www.fda.gov/CDRHWebinar.
Note: The FDA does not provide Continuing Education Credits (CEU) or Certificates of Attendance for webinar attendance.
If you have any general questions about the FDA’s regulation of medical devices, please contact CDRH’s Division of Industry and Consumer Education (DICE) at dice@fda.hhs.gov, 1-800-638-2041, or 301-796-7100.
Thank you,
 Food and Drug Administration
Center for Devices and Radiological Health

Helene Clayton-Jeter, O.D.
Office of Health and Constituent Affairs
Food and Drug Administration
For more information about the Cardiovascular & Endocrine Liaison Program visit the FDA Patient Network

No hay comentarios:

Publicar un comentario